You are not logged in.

Generation of mutant leukaemia inhibitory factor (LIF)-IgG heavy chain fusion proteins as bivalent antagonists of LIF

Jazayeri, Jalal A., De Weerd, Nicole, Raye, Warren, Velkov, Tony, Santos, Lanie, Taylor, David and Carroll, Graeme J. 2007, Generation of mutant leukaemia inhibitory factor (LIF)-IgG heavy chain fusion proteins as bivalent antagonists of LIF, Journal of immunological methods, vol. 323, no. 1, pp. 1-10, doi: 10.1016/j.jim.2007.02.011.

Attached Files
Name Description MIMEType Size Downloads

Title Generation of mutant leukaemia inhibitory factor (LIF)-IgG heavy chain fusion proteins as bivalent antagonists of LIF
Author(s) Jazayeri, Jalal A.
De Weerd, Nicole
Raye, Warren
Velkov, Tony
Santos, Lanie
Taylor, David
Carroll, Graeme J.
Journal name Journal of immunological methods
Volume number 323
Issue number 1
Start page 1
End page 10
Publisher Elsevier
Place of publication Amsterdam, Netherlands
Publication date 2007-05-31
ISSN 0022-1759
1872-7905
Keyword(s) cytokines
leukaemia inhibitory factor (LIF)
Fc proteins
insect cell expression
Summary Two leukaemia inhibitory factor (LIF) mutants, designated MH35-BD and LIF05, have been shown to have a capacity to inhibit the biological activities of not only human LIF (hLIF) but also other interleukin-6 (IL-6) subfamily cytokines such as human oncostatin M (hOSM). These cytokines share the same receptor complex in which the glycoprotein 130 (gp130) subunit is a common constituent. However, at low concentrations and in their monomeric forms, such molecules have a relatively short plasma half-life due to rapid clearance from the kidneys. Here, to prolong their serum half-lives, we have used a multi-step polymerase chain reaction (PCR) to fuse each of the LIF05 and MH35-BD cDNA fragments to a sequence encoding the Fc portion, and the hinge region, of the human immunoglobulin G (hIgG) heavy chain. The linking was achieved through an oligomer encoding a thrombin-sensitive peptide linker thus generating MH35-BD:Fc and LIF05:Fc, respectively. Both Fc fusion constructs were expressed in insect cell Sf21 and the proteins were purified by two successive affinity chromatography steps using nickel–nitrilotriacetic acid (Ni–NTA) agarose and protein A beads. The Ba/F3 cell-based proliferation assay was used to confirm that the proteins were biologically active. In addition, preliminary pharmacokinetics indicates that the Fc fusion constructs have a longer serum half-life compared to their non-fusion counterparts.
Language eng
DOI 10.1016/j.jim.2007.02.011
Field of Research 030104 Immunological and Bioassay Methods
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2007, Elsevier B.V.
Persistent URL http://hdl.handle.net/10536/DRO/DU:30019353

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in TR Web of Science
Scopus Citation Count Cited 6 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 382 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Fri, 11 Sep 2009, 10:54:54 EST by Rachael Wilson

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.